Genmab - ADR Aktie News

Media Release COPENHAGEN, Denmark; January 5, 2026 Genmab A/S  (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 44 th  Annual J.P. Morgan Healthcare Conference in San Francisco at 3:45 PM PST / 6: 45 PM EST on January 1 3 , 202 6 , 12: 45  AM CET on January 1 4 , 202 6 . The live and archived webcast of the presentation will be availabl...

Genmab will stop development of its experimental antibody therapy to treat cancer that was in late-stage trials, the Danish drugmaker said on Monday.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab's strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape. While the clinical profile observed to date ...

Company Announcement Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher ‑ impact opportunities across Genmab's late ‑ stage pipeline and increasingly competitive landscape This decision does not impact Genmab's full ‑ year 2025 financial guidance COPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) anno...

Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced tender offer (the “Offer”) by Genmab Holding II B.V., a wholly owned subsidiary of Genmab (“Purchaser”), to acquire all the issued and outstanding common shares of Merus N.V. (Nasdaq: MRUS) (“Merus”) for $97 per commo...

Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to Genmab's EBITDA by end of 2029 COPENHAGEN, Denmark; December 12, 2025 – Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that the conditions, including the minimum tender condition, to the previously announced ten...

Genmab A/S (GMAB) Discusses 2025 R&D Progress, ASH Data Review, and Strategic Pipeline Additions Transcript